secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2023-01-20T23:59:59+00:00
Accession:  0001867096-23-000006
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma amends credit deal to allow Letter of Financial Support to Australian unit
--------------------------------------------------------------------------------

- Amendment No. 2 signed Jan 19, 2023; permits Xeris Pharma to issue a Letter of Financial Support to its Australian subsidiary.
- Amendment modifies Credit Agreement dated March 8, 2022, with Hayfin Services as administrative agent.
- No changes to principal, interest rate, or maturity under the existing credit facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000006/0001867096-23-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000006/xers-20230119.htm
  HTML page:      https://secwatch.observer/filing/0001867096-23-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer